4651-98-3

Basic information

• Product Name: METHYL 2-AMINO-4-METHYL-3-THIOPHENE CARBOXYLATE
• Synonyms: METHYL 2-AMINO-4-METHYL-3-THIOPHENE CARBOXYLATE
• CAS NO: 4651-98-3
• Molecular Formula: C₇H₉NO₂S
• Molecular Weight: 171.22
• Mol File: 4651-98-3.mol
• Article Data: 4

Chemical Properties

• Melting Point: 111-112°C
• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: METHYL 2-AMINO-4-METHYL-3-THIOPHENE CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-AMINO-4-METHYL-3-THIOPHENE CARBOXYLATE(4651-98-3)
• EPA Substance Registry System: METHYL 2-AMINO-4-METHYL-3-THIOPHENE CARBOXYLATE(4651-98-3)

Safety Data

• Hazardous Substances Data: 4651-98-3(Hazardous Substances Data)

Usage

General Description

Methyl 2-amino-4-methyl-3-thiophene carboxylate is a specific type of chemical compound. It is characterized by its molecular formula, C7H9NO2S, and defined by structural components including a methyl group, an amino group, a thiophene ring, and a carboxylate group. METHYL 2-AMINO-4-METHYL-3-THIOPHENE CARBOXYLATE can be involved in a variety of chemical reactions and is often used as a reactant or intermediate in the synthesis of other chemical products. Like many other chemicals, it must be handled with care due to potential risks associated with its use. The particular properties and uses of this compound may vary based on its specific applications within the field of chemistry.

Upstream product

• 110-89-4 piperidine 
• 55704-78-4 2,5-dihydroxy-2,5-dimethyl-1,4-dithiane 
• 105-34-0 methyl 2-cyanoacetate 
• 67-64-1 acetone 
• 6666-75-7 methyl 2-cyano-3-methylbut-2-enoate 

Downstream Products

• 126637-05-6 3-Allyl-2-mercapto-5-methyl-3H-thieno[2,3-d]pyrimidin-4-one 
• 179338-12-6 4-methyl-2-[2-(3-phenoxyphenyl)acetylamino]-thiophene-3-carboxylic acid methyl ester 
• 43088-64-8 5-methylthieno[2,3-d]pyrimidin-4-ol 
• 75860-79-6 5-methylthieno<2,3-d>pyrimidine-2,4-dione 
• 1239461-51-8 N-(4-methyl-3-(3-methyl-1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(4-(3-(piperidin-1-yl)propoxy)phenyl)acetamide 
• 1239461-71-2 N-(4-methyl-3-(5-methyl-4H-1,2,4-triazol-3-yl)thiophen-2-yl)-2-(4-(pyridin-4-yl)phenyl)acetamide 
• 1239461-00-7 2-(4-methoxyphenyl)-N-(4-methyl-3-(3-methyl-1H-1,2,4-triazol-5-yl)thiophen-2-yl)acetamide 
• 1239461-50-7 4-methyl-2-(2-(4-(3-(piperidin-1-yl)propoxy)phenyl)-acetamido)thiophene-3-carboxamide 
• 1292805-26-5 C₁₉H₁₇N₃O₂S 

Relevant articles and documents

Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB2R Ligands

Herein we describe the design and synthesis of a new series of heteroarylpyrimidine/heteroaryltriazine derivatives on the basis of quinazoline-2,4(1H,3H)-diones as CB2R-selective ligands using a bioisosterism strategy. An acetamide group was explored to displace the enamine linker of the lead compound for the purpose of stereoisomerism elimination and hydrophilicity increase. As a result, some of the synthesized compounds showed high bioactivity and selectivity for CB2R in calcium mobilization assays, and four displayed CB2R agonist activity, with EC50 values below 30 nm. The compound exhibiting the highest agonist activity toward CB2R (EC50=7.53±3.15 nm) had a selectivity over CB1R of more than 1328-fold. Moreover, structure–activity relationship (SAR) studies indicated that the substituents on the nucleus play key roles in the functionality of a ligand, with one such example demonstrating CB2R antagonist activity. Additionally, molecular docking simulations were conducted with the aim of better understanding of these new derivatives in relation to the structural requirements for agonists/antagonists binding to CB2R.

Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors

Inactivation of the NF-κB signaling pathway by inhibition of IKKβ is a well-known approach to treat inflammatory diseases such as rheumatoid arthritis and cancer. Thienopyrimidine-based analogues were designed through modification of the known IKKβ inhibitor, SPC-839, and then biologically evaluated. The resulting analogues had good inhibitory activity against both nitric oxide and TNF-α, which are well-known inflammatory responses generated by activated NF-κB. However, no inhibitory activity against IKKβ was observed with these compounds. The thienopyrimidine-based analogues were subsequently screened for a target kinase, and FLT3, which is a potential target for acute myeloid leukemia (AML), was identified. Thienopyrimidine-based FLT3 inhibitors showed good inhibition profiles against FLT3 under 1 μM. Overall, these compounds represent a promising family of inhibitors for future development of a treatment for AML.